Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATG4B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATG4B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATG4B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATG4B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATG4B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ATG4B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ATG4B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:0045732 | Colorectum | AD | positive regulation of protein catabolic process | 92/3918 | 231/18723 | 3.85e-11 | 4.47e-09 | 92 |
GO:0016236 | Colorectum | AD | macroautophagy | 103/3918 | 291/18723 | 6.76e-09 | 4.15e-07 | 103 |
GO:00421761 | Colorectum | SER | regulation of protein catabolic process | 126/2897 | 391/18723 | 5.33e-17 | 2.52e-14 | 126 |
GO:00457321 | Colorectum | SER | positive regulation of protein catabolic process | 77/2897 | 231/18723 | 9.91e-12 | 1.90e-09 | 77 |
GO:00098961 | Colorectum | SER | positive regulation of catabolic process | 132/2897 | 492/18723 | 4.16e-11 | 6.72e-09 | 132 |
GO:00162361 | Colorectum | SER | macroautophagy | 79/2897 | 291/18723 | 1.97e-07 | 1.10e-05 | 79 |
GO:00421762 | Colorectum | MSS | regulation of protein catabolic process | 145/3467 | 391/18723 | 2.03e-18 | 1.17e-15 | 145 |
GO:00098962 | Colorectum | MSS | positive regulation of catabolic process | 163/3467 | 492/18723 | 3.10e-15 | 9.22e-13 | 163 |
GO:00457322 | Colorectum | MSS | positive regulation of protein catabolic process | 85/3467 | 231/18723 | 3.66e-11 | 4.57e-09 | 85 |
GO:00162362 | Colorectum | MSS | macroautophagy | 93/3467 | 291/18723 | 2.08e-08 | 1.17e-06 | 93 |
GO:00098964 | Colorectum | FAP | positive regulation of catabolic process | 126/2622 | 492/18723 | 3.76e-12 | 2.56e-09 | 126 |
GO:00421764 | Colorectum | FAP | regulation of protein catabolic process | 106/2622 | 391/18723 | 5.00e-12 | 3.06e-09 | 106 |
GO:00457324 | Colorectum | FAP | positive regulation of protein catabolic process | 61/2622 | 231/18723 | 4.38e-07 | 2.35e-05 | 61 |
GO:00162363 | Colorectum | FAP | macroautophagy | 70/2622 | 291/18723 | 2.73e-06 | 1.02e-04 | 70 |
GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
GO:0045732111 | Esophagus | ESCC | positive regulation of protein catabolic process | 167/8552 | 231/18723 | 1.47e-16 | 1.14e-14 | 167 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATG4B | SNV | Missense_Mutation | novel | c.1144N>T | p.Asp382Tyr | p.D382Y | Q9Y4P1 | protein_coding | deleterious(0.02) | benign(0.022) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATG4B | SNV | Missense_Mutation | novel | c.686N>A | p.Arg229His | p.R229H | Q9Y4P1 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATG4B | SNV | Missense_Mutation | | c.246N>G | p.Ile82Met | p.I82M | Q9Y4P1 | protein_coding | tolerated(0.64) | benign(0.137) | TCGA-AX-A1CP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATG4B | SNV | Missense_Mutation | rs756120336 | c.628G>A | p.Ala210Thr | p.A210T | Q9Y4P1 | protein_coding | tolerated(0.42) | benign(0.012) | TCGA-B5-A0JU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATG4B | SNV | Missense_Mutation | novel | c.467N>T | p.Ala156Val | p.A156V | Q9Y4P1 | protein_coding | tolerated(0.34) | benign(0.074) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATG4B | SNV | Missense_Mutation | rs571586050 | c.445G>A | p.Ala149Thr | p.A149T | Q9Y4P1 | protein_coding | deleterious(0.02) | probably_damaging(0.978) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ATG4B | SNV | Missense_Mutation | | c.952G>A | p.Ala318Thr | p.A318T | Q9Y4P1 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-D1-A163-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
ATG4B | SNV | Missense_Mutation | novel | c.428N>G | p.Tyr143Cys | p.Y143C | Q9Y4P1 | protein_coding | deleterious(0) | possibly_damaging(0.463) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ATG4B | SNV | Missense_Mutation | novel | c.1048N>A | p.Glu350Lys | p.E350K | Q9Y4P1 | protein_coding | deleterious(0.01) | probably_damaging(0.96) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ATG4B | SNV | Missense_Mutation | novel | c.979G>T | p.Asp327Tyr | p.D327Y | Q9Y4P1 | protein_coding | deleterious(0.02) | possibly_damaging(0.617) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | TOLFENAMIC ACID | TOLFENAMIC ACID | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | DOXYCYCLINE HYCLATE | DOXYCYCLINE HYCLATE | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | GNF-PF-4085 | CHEMBL528181 | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | SJ000196127 | CHEMBL605084 | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | ALEXIDINE HYDROCHLORIDE | ALEXIDINE HYDROCHLORIDE | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | GNF-PF-2272 | CHEMBL601757 | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | NSC-95397 | CHEMBL429095 | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | BIFONAZOLE | BIFONAZOLE | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | 9,10-PHENANTHRENEQUINONE | 9,10-PHENANTHRENEQUINONE | |
23192 | ATG4B | ENZYME, DRUGGABLE GENOME, PROTEASE | | FENTICLOR | FENTICLOR | |